Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05003843

BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis

The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are eligible for treatment.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sharp Grossmont, La Mesa, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Unilateral lower extremity DVT occlusion involving iliac and/or common femoral veins with up to 2 cm extension in the inferior vena cava (IVC) or femoral in combination with iliac veins, including patients with extension of clot into the contralateral common iliac vein Note: Patients with non-iliofemoral DVT in the contralateral limb, who do not require endovascular treatment, may be enrolled
  • Acute thrombotic or thromboembolic occlusion with symptom duration of 14 days or less at presentation
  • Frontline treatment with Indigo Aspiration System in the target venous segment per Investigator decision
  • Patient is ≥18 years of age
  • Informed consent is obtained per Institutional Review Board requirements

Exclusion criteria

  • Contraindication to systemic or therapeutic doses of anticoagulants
  • Contraindication to iodinated contrast venography that cannot be adequately premedicated
  • Complete infrarenal IVC occlusion
  • In the index leg: prior DVT
  • Prior stent in target venous segment
  • Treatment of index DVT with thrombolytics within 14 days prior to index procedure
  • Pulmonary embolism (PE) defined as either high (systolic blood pressure < 90 mmHg and/or patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low risk PE and/or intermediate low risk PE can be enrolled.
  • Known coagulation disorders both acquired (e.g., Heparin Induced Thrombocytopenia, etc.) or genetic (e.g., Factor V Leiden, etc.), thrombophilia, or hypercoagulable state
  • Pregnant patients
  • Life expectancy <1 year due to comorbidities
  • Primary brain, metastatic cancer or marrow malignancies
  • Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.
  • Other medical, behavioral, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study
  • Pre-existing malpositioned stent(s) that obstructs the ostium of the index iliac vein and contacts the vena cava wall as demonstrated by venography prior to the index procedure
  • Congenital anatomic anomalies of the IVC or iliac veins

Treatment and study plan

Indigo Aspiration System

Device

Indigo Aspiration System

Primary outcomes

  1. Composite of Major Adverse Events

    Time frame: 48 Hours Post-Procedure

    Device related death, major bleeding, new symptomatic pulmonary embolism or re-thrombosis of the target venous segment and serious device related events

  2. Change in Marder Score

    Time frame: Index Procedure

    Complete or near complete (75% or greater) reduction of venous thrombus from the target venous segment as measured by Marder Score pre- to post-procedure

    The Marder Score ranges from 0 to 24, with higher scores being worse.

Secondary outcomes

  1. Composite of Major Adverse Events

    Time frame: 30 Days Post-Procedure

    A composite of death, major bleeding, new symptomatic pulmonary embolism or re-thrombus of the target venous segment

  2. Device Related Adverse Events

    Time frame: 24 Months

    Proportion of participants with device related adverse events

  3. Villalta Scale

    Time frame: 24 Months

    Villalta scores reported at baseline, 30 days, 180 days, 12 months, and 24 months

    Villalta score ranges from 0 (no post thrombotic syndrome) to 33 (severe post thrombotic syndrome), with higher scores being worse.

Sponsors and collaborators

Lead sponsor

Penumbra Inc.

Industry

Registry information

Official study title

BOLT: A Prospective, Multicenter Study of Patients With Deep Vein Thrombosis to Evaluate the Safety and Efficacy of the Indigo® Aspiration System

Important dates

Study start
2021
Primary completion
2025
Study completion
2028
First posted
Aug 12, 2021
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.